Progenics Pharmaceuticals Announces Second Quarter 2017 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Progenics Pharma (PGNX) Misses Q2 EPS by 3c; Sees AZEDRA NDA in August
August 9, 2017 7:36 AM EDTProgenics Pharma (NASDAQ: PGNX) reported Q2 EPS of ($0.24), $0.03 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $3.68 million.
NDA (New Drug Application) for AZEDRA® Expected to be Submitted to U.S. Food and Drug... More
